MXPA04006543A - Terapia combinada contra tumores, que comprende derivados de acriloildistamicina sustituida e inhibidores de serina/treonina cinasa. - Google Patents

Terapia combinada contra tumores, que comprende derivados de acriloildistamicina sustituida e inhibidores de serina/treonina cinasa.

Info

Publication number
MXPA04006543A
MXPA04006543A MXPA04006543A MXPA04006543A MXPA04006543A MX PA04006543 A MXPA04006543 A MX PA04006543A MX PA04006543 A MXPA04006543 A MX PA04006543A MX PA04006543 A MXPA04006543 A MX PA04006543A MX PA04006543 A MXPA04006543 A MX PA04006543A
Authority
MX
Mexico
Prior art keywords
serine
inhibitors
distamycin derivatives
acryloyl distamycin
kinase
Prior art date
Application number
MXPA04006543A
Other languages
English (en)
Inventor
Paolo Cozzi
Original Assignee
Pharmacia Italia Spa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmacia Italia Spa filed Critical Pharmacia Italia Spa
Publication of MXPA04006543A publication Critical patent/MXPA04006543A/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/13Amines
    • A61K31/155Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4025Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4151,2-Diazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/04Antineoplastic agents specific for metastasis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Abstract

La presente invencion provee el uso combinado de derivados de acriloildistamicina, en particular derivados de -bromo y -cloro-acriloildistamicina de formula (I), como se indica en la especificacion, y un inhibidor de proteina cinasa, particularmente serina/treonina y tirosina cinasas, en el tratamiento de tumores, tambien se provee el uso de dichas combinaciones en el tratamiento o prevencion de metastasis o en el tratamiento de tumores por inhibicion de angiogenesis.
MXPA04006543A 2002-01-02 2002-12-18 Terapia combinada contra tumores, que comprende derivados de acriloildistamicina sustituida e inhibidores de serina/treonina cinasa. MXPA04006543A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP02075052 2002-01-02
PCT/EP2002/013092 WO2003055522A1 (en) 2002-01-02 2002-12-18 Combined therapy against tumors comprising substituted acryloyl distamycin derivatives and protein kinase (serine/threonine kinase) inhibitors

Publications (1)

Publication Number Publication Date
MXPA04006543A true MXPA04006543A (es) 2004-10-04

Family

ID=8185508

Family Applications (1)

Application Number Title Priority Date Filing Date
MXPA04006543A MXPA04006543A (es) 2002-01-02 2002-12-18 Terapia combinada contra tumores, que comprende derivados de acriloildistamicina sustituida e inhibidores de serina/treonina cinasa.

Country Status (24)

Country Link
US (1) US20060084612A1 (es)
EP (1) EP1461083B1 (es)
JP (1) JP2005516025A (es)
KR (1) KR20040078118A (es)
CN (1) CN1617744A (es)
AT (1) ATE321572T1 (es)
AU (1) AU2002352090B8 (es)
BR (1) BR0215454A (es)
CA (1) CA2472008C (es)
CY (1) CY1105269T1 (es)
DE (1) DE60210329T2 (es)
DK (1) DK1461083T3 (es)
ES (1) ES2263835T3 (es)
HU (1) HUP0402639A3 (es)
IL (2) IL162820A0 (es)
MX (1) MXPA04006543A (es)
NO (1) NO20043217L (es)
NZ (1) NZ533854A (es)
PL (1) PL371179A1 (es)
PT (1) PT1461083E (es)
RU (1) RU2328306C2 (es)
SI (1) SI1461083T1 (es)
WO (1) WO2003055522A1 (es)
ZA (1) ZA200405290B (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20130016413A (ko) * 2002-07-30 2013-02-14 아에테르나 젠타리스 게엠베하 항종양 약제와 조합하여 사용하기 위한 알킬포스포콜린의 약물 제품
US8383605B2 (en) 2002-07-30 2013-02-26 Aeterna Zentaris Gmbh Use of alkylphosphocholines in combination with antimetabolites for the treatment of benign and malignant oncoses in humans and mammals
AU2006233856A1 (en) * 2005-04-08 2006-10-19 Nerviano Medical Sciences S.R.L. Antitumor combination comprising substituted acryloyl distamycin derivatives and antibodies inhibiting growth factors or their receptors
WO2011123691A1 (en) 2010-03-31 2011-10-06 Keryx Biopharmaceuticals, Inc. Perifosine and capecitabine as a combined treatment for cancer

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6274576B1 (en) * 1995-06-27 2001-08-14 The Henry Jackson Foundation For The Advancement Of Military Medicine Method of dynamic retardation of cell cycle kinetics to potentiate cell damage
GB9615692D0 (en) * 1996-07-25 1996-09-04 Pharmacia Spa Acryloyl substituted distamycin derivatives, process for preparing them, and their use as antitumor and antiviral agents
GB0015447D0 (en) * 2000-06-23 2000-08-16 Pharmacia & Upjohn Spa Combined therapy against tumors comprising substituted acryloyl derivates and alkylating agents
GB0015444D0 (en) * 2000-06-23 2000-08-16 Pharmacia & Upjohn Spa Combined therapy against tumors comprising substituted acryloyl distamycin derivatives and topoisomerase I and II inhibitors

Also Published As

Publication number Publication date
KR20040078118A (ko) 2004-09-08
HUP0402639A2 (hu) 2005-04-28
CA2472008C (en) 2009-07-28
HUP0402639A3 (en) 2012-02-28
EP1461083B1 (en) 2006-03-29
NZ533854A (en) 2007-05-31
US20060084612A1 (en) 2006-04-20
CN1617744A (zh) 2005-05-18
WO2003055522A1 (en) 2003-07-10
JP2005516025A (ja) 2005-06-02
SI1461083T1 (sl) 2006-08-31
AU2002352090B2 (en) 2008-05-15
DK1461083T3 (da) 2006-07-10
CY1105269T1 (el) 2010-03-03
DE60210329D1 (de) 2006-05-18
PT1461083E (pt) 2006-08-31
AU2002352090A1 (en) 2003-07-15
IL162820A (en) 2010-04-15
ES2263835T3 (es) 2006-12-16
EP1461083A1 (en) 2004-09-29
RU2328306C2 (ru) 2008-07-10
PL371179A1 (en) 2005-06-13
NO20043217L (no) 2004-07-30
DE60210329T2 (de) 2006-11-30
CA2472008A1 (en) 2003-07-10
RU2004123641A (ru) 2005-06-10
AU2002352090B8 (en) 2008-06-19
ATE321572T1 (de) 2006-04-15
ZA200405290B (en) 2005-06-17
BR0215454A (pt) 2004-11-23
IL162820A0 (en) 2005-11-20

Similar Documents

Publication Publication Date Title
MY141739A (en) Substituted quinazoline derivatives as inhibitors of aurora kinases
ATE297394T1 (de) Jun kinase inhibitoren
YU84603A (sh) Novi inhibitori tirozin kinaze
MXPA03010961A (es) Compuestos de tiazol utiles como inhibidores de proteinas cinasas.
IL191832A (en) Pyridiazinone compounds and their use in the preparation of drugs for the treatment of tumors
MXPA02005844A (es) Inhibidores de cinasas de proteina.
WO2004096795A3 (en) C-fms kinase inhibitors
HK1093159A1 (en) Monocyclic heterocycles as kinase inhibitors
WO2006047479A3 (en) C-fms kinase inhibitors
WO2004030620A3 (en) Novel tyrosine kinase inhibitors
MXPA05009151A (es) Inhibidores de cinasa heterociclica.
GB0015444D0 (en) Combined therapy against tumors comprising substituted acryloyl distamycin derivatives and topoisomerase I and II inhibitors
MXPA02010759A (es) Derivados del acido (2-oxindol-3-ilidenil) acetico y su uso como inhibidores de la proteina quinasa.
CY1105269T1 (el) Συνδυασμενη θepαπεια εναντι ογκων που πepιλαμβανει υποκατεστημενα παραγωγα ακρυλοϋλ δισταμυκινης και αναστολεις κινασης πρωτεϊνης (κιναση σepινης/θρεονινης)
MXPA03004023A (es) Compuestos quimicos.
WO2001097790A3 (en) Combined therapy against tumors comprising substituted acryloyl distamycin derivatives and alkylating agents
AU2003236701A8 (en) Guanidino phenylalanin compounds used as urokinase inhibitors
MXPA02012165A (es) Terapia combinada contra tumores que comprende derivados de acriloil-distamicina sustituida, taxanos y/o antimetabolitos.
TW200602023A (en) Monocyclic heterocycles as kinase inhibitors
UA90254C2 (ru) Производные пиразола и их применение в качестве ингибиторов рецепторных тирозинкиназ

Legal Events

Date Code Title Description
FG Grant or registration